On May 8, 2025, Scotiabank released an updated evaluation for Apellis Pharmaceuticals (APLS, Financial). In its latest assessment, analyst Greg Harrison maintained the company's rating at "Sector Perform." Despite retaining the same rating, Scotiabank adjusted its price target for APLS, lowering it from the previous figure of $28.00 to a new target of $20.00.
This adjustment indicates a significant decrease of 28.57% in the price target, as noted in the report. The analysis by Scotiabank reflects the evolving market conditions and company performance expectations.
Investors in Apellis Pharmaceuticals (APLS, Financial) should take note of these changes, as they reflect the latest insights provided by Scotiabank's analyst, Greg Harrison. The stock continues to be monitored under the "Sector Perform" rating, which suggests that it is expected to perform in line with the industry average.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 20 analysts, the average target price for Apellis Pharmaceuticals Inc (APLS, Financial) is $38.75 with a high estimate of $75.00 and a low estimate of $18.00. The average target implies an upside of 118.68% from the current price of $17.72. More detailed estimate data can be found on the Apellis Pharmaceuticals Inc (APLS) Forecast page.
Based on the consensus recommendation from 23 brokerage firms, Apellis Pharmaceuticals Inc's (APLS, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Apellis Pharmaceuticals Inc (APLS, Financial) in one year is $227.76, suggesting a upside of 1185.33% from the current price of $17.72. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Apellis Pharmaceuticals Inc (APLS) Summary page.
